Asia-Pacific syndromic multiplex diagnostic market is projected to register a CAGR of 8.4% in the forecast period of 2020 to 2027. The new market report contains data for historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
Asia-Pacific Syndromic Multiplex Diagnostic Market, By Products and Services (Reagents & Consumables, Instruments & Accessories, Software & Services), Infection Type (Viral, Bacterial, Parasites, Fungal & Others), Disease (Respiratory Infections, Gastroenteritis, Sexually Transmitted Infections, Hepatitis, Tropical Fever, Meningitis, Childhood Infections, Immunosuppression & Eye Infections), Panels Type (Respiratory Panel, GI-Enteric Panel, Sexually Transmitted Disease Panel, Blood-Sepsis Panel, Meningitis Panel & Others), End User (Hospitals, Clinical Laboratories, Pharmaceutical & Biotechnology Companies, Research Institutes, Physician Office Lab's & Others), Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines & Rest of Asia-Pacific) Industry Trends and Forecast to 2027
Some of the major factors contributing to the growth of the Asia-Pacific syndromic multiplex diagnostic market are:
• Rising geriatric population in the region
• Growing prevalence of infection diseases
Market Players:
The key market players for Asia-Pacific syndromic multiplex diagnostic market are listed below:
• GenMark Diagnostics, Inc.
• QuantuMDx Group Ltd.
• BioFire Diagnostics (a subsidiary of bioMérieux SA)
• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific Inc.
• Siemens Healthcare GmbH
• QIAGEN
• Hologic, Inc.
• F. Hoffmann-La Roche Ltd
• BD
• Danaher
• Curetis
• Abbott
• DiaSorin S.p.A.
• Bosch Healthcare Solutions GmbH (a subsidiary of Robert Bosch GmbH)
• Biocartis
• Luminex Corporation
• Seegene Inc.